Penserra Capital Management LLC Takes Position in ADMA Biologics Inc (NASDAQ:ADMA)

Penserra Capital Management LLC bought a new stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 115,603 shares of the biotechnology company's stock, valued at approximately $2,293,000.

Other large investors have also recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new stake in shares of ADMA Biologics during the fourth quarter valued at $19,076,000. JPMorgan Chase & Co. boosted its stake in shares of ADMA Biologics by 272.5% during the fourth quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company's stock valued at $13,159,000 after purchasing an additional 561,310 shares during the period. Victory Capital Management Inc. boosted its stake in shares of ADMA Biologics by 52.8% during the fourth quarter. Victory Capital Management Inc. now owns 109,948 shares of the biotechnology company's stock valued at $1,886,000 after purchasing an additional 38,002 shares during the period. Sei Investments Co. boosted its stake in shares of ADMA Biologics by 147.2% during the fourth quarter. Sei Investments Co. now owns 527,272 shares of the biotechnology company's stock valued at $9,043,000 after purchasing an additional 314,013 shares during the period. Finally, Swiss National Bank boosted its stake in shares of ADMA Biologics by 6.6% during the fourth quarter. Swiss National Bank now owns 458,400 shares of the biotechnology company's stock valued at $7,862,000 after purchasing an additional 28,500 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on ADMA shares. Raymond James Financial upped their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th.

ADMA Biologics Stock Down 2.2%

NASDAQ:ADMA opened at $17.88 on Tuesday. ADMA Biologics Inc has a 1-year low of $10.21 and a 1-year high of $25.67. The company has a 50-day moving average of $20.11 and a 200 day moving average of $18.74. The firm has a market cap of $4.27 billion, a PE ratio of 21.04 and a beta of 0.43. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The business had revenue of $114.80 million during the quarter, compared to analysts' expectations of $116.40 million. ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The firm's revenue was up 40.2% compared to the same quarter last year. During the same period last year, the company earned $0.08 earnings per share. As a group, research analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other ADMA Biologics news, Director Jerrold B. Grossman sold 10,000 shares of the business's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the transaction, the director directly owned 478,194 shares in the company, valued at approximately $10,190,314.14. The trade was a 2.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Lawrence P. Guiheen sold 20,000 shares of the business's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the transaction, the director owned 94,830 shares of the company's stock, valued at $1,987,636.80. This represents a 17.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 464,621 shares of company stock worth $9,644,269. 3.70% of the stock is owned by corporate insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.